CoChat

A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

Raghu, Ganesh, Mouded, Majd, Chambers, Daniel C., Martinez, Fernando J., Richeldi, Luca, Lancaster, Lisa H., Hamblin, Mark J., Gibson, Kevin F., Rosas, Ivan O., Prasse, Antje, Zhao, Guolin, Serenko, Michael, Novikov, Natasha, McCurley, Amy, Bansal, Prashant, Stebbins, Christopher, Arefayene, Million, Ibebunjo, Stella, Violette, Shelia M., Gallagher, Diana, Behr, Jürgen · 2022 · American Journal of Respiratory and Critical Care Medicine
Cited by 100

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Rationale: Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. Objectives: To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in the treatment of patients with IPF. Methods: In a phase IIb randomized, double-blind, placebo-controlled trial, patients with IPF (FVC ⩾50% predicted, on or off background therapy) were randomized 1:1 to once-weekly subcutaneous BG00011 56 mg or placebo. The primary endpoint was FVC change from baseline at Week 52. Because of early trial termination (imbalance in adverse events and lack of clinical benefit), endpoints were evaluated at Week 26 as an exploratory analysis. Measurements and Main Results: One hundred six patients were randomized and received at least one dose of BG00011 (n = 54) or placebo (n = 52). At Week 26, there was no significant difference in FVC change from baseline between patients who received BG00011 (n = 20) or placebo (n = 23), least squares mean (SE) −0.097 L (0.0600) versus −0.056 L (0.0593), respectively (P = 0.268). However, after Week 26, patients in the BG00011 group showed a worsening trend. Eight (44.4%) of 18 who received BG00011 and 4 (18.2%) of 22 who received placebo showed worsening of fibrosis on high-resolution computed tomography at the end of treatment. IPF exacerbation/or progression was reported in 13 patients (all in the BG00011 group). Serious adverse events occurred more frequently in BG00011 patients, including four deaths. Conclusions: The results do not support the continued clinical development of BG00011. Further research is warranted to identify new treatment strategies that modify inflammatory and fibrotic pathways in IPF. Clinical trial registered with www.clinicaltrials.gov (NCT03573505).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202112-2824oc

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 100

Metadata

Authors
Raghu, G., Mouded, M., Chambers, D. C., Martinez, F. J., Richeldi, L., Lancaster, L. H., Hamblin, M. J., Gibson, K. F., Rosas, I. O., Prasse, A., Zhao, G., Serenko, M., Novikov, N., McCurley, A., Bansal, P., Stebbins, C., Arefayene, M., Ibebunjo, S., Violette, S. M., Gallagher, D., & Behr, J.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2022-11-01
Volume
206
Issue
9
Pages
1128-1139
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4283747664
Cited by
100
References
16
FWCI
10.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.202112-2824oc
The paper
Raghu, G., Mouded, M., Chambers, D. C., Martinez, F. J., Richeldi, L., Lancaster, L. H., Hamblin, M. J., Gibson, K. F., Rosas, I. O., Prasse, A., Zhao, G., Serenko, M., Novikov, N., McCurley, A., Bansal, P., Stebbins, C., Arefayene, M., Ibebunjo, S., Violette, S. M., . . . Behr, J. (2022). A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202112-2824oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.